Patents by Inventor Bent Højgaard

Bent Højgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pulsatile drug delivery system for treating morning akinesia
    Patent number: 11975104
    Abstract: Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: May 7, 2024
    Assignee: Contera Pharma A/S
    Inventors: John Bondo Hansen, Mikael Søndergård Thomsen, Ann Vivian Fullerton, Bent Højgaard, Peter Gudmund Nielsen
  • Composition comprising suplatast tosilate
    Patent number: 11819482
    Abstract: Provided is a pharmaceutical composition comprising suplatast tosilate or pharmaceutically acceptable derivatives thereof that provides for a constant exposure of the compound.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: November 21, 2023
    Assignees: Conrig Pharma ApS, Solural Pharma ApS
    Inventors: John Bondo Hansen, Mikael Søndergård Thomsen, Bent Højgaard
  • PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS
    Publication number: 20230114865
    Abstract: The disclosure relates to oral formulations for gastric delivery of a pharmaceutically acceptable salt of a phenyl pyrrole aminoguanidine compound.
    Type: Application
    Filed: December 14, 2022
    Publication date: April 13, 2023
    Inventors: Thomas BOESEN, Thomas Engelbrecht Nordkild JONASSEN, Bent HØJGAARD
  • TESOFENSINE AND BETA BLOCKER COMBINATION FORMULATIONS
    Publication number: 20230092397
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Application
    Filed: August 24, 2022
    Publication date: March 23, 2023
    Inventors: Peter G. NIELSEN, Mikael S. THOMSEN, Bent HØJGAARD
  • PULSATILE DRUG DELIVERY SYSTEM FOR TREATING MORNING AKINESIA
    Publication number: 20230078925
    Abstract: Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.
    Type: Application
    Filed: September 7, 2022
    Publication date: March 16, 2023
    Inventors: John Bondo HANSEN, Mikael Søndergård THOMSEN, Ann FULLERTON, Bent HØJGAARD, Peter Gudmund NIELSEN
  • Methotrexate Dosage Form
    Publication number: 20230051463
    Abstract: The present invention relates to a pharmaceutical dosage form comprising an active ingredient such as methotrexate or a pharmaceutically acceptable salt thereof, in particular in the form of pellets, such as multiparticulates, mini-tablets or granulate. It further relates to oral dosage forms for which saturation kinetics limits the oral use of higher dosages of active ingredients.
    Type: Application
    Filed: January 26, 2021
    Publication date: February 16, 2023
    Inventors: Bent HØJGAARD, Hanne DAMGAARD JENSEN
  • Tesofensine and beta blocker combination formulations
    Patent number: 11426383
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: August 30, 2022
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • COMPRESSED SOLID COMPOSITION FOR MRI
    Publication number: 20220257802
    Abstract: The present invention relates to a compressed solid composition for MRI comprising a physiologically acceptable manganese (II) compound, its preparation and use for preparing an oral solution.
    Type: Application
    Filed: June 8, 2020
    Publication date: August 18, 2022
    Applicant: Ascelia Pharma AB
    Inventors: Bent Højgaard, Magnus Olafsson Corfitzen, Dorthe Da Graca Couto Thrige
  • Solid oral dosage form of lipophilic compounds
    Patent number: 11197828
    Abstract: The present invention relates to a pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: December 14, 2021
    Assignee: SOLURAL PHARMA APS
    Inventor: Bent Højgaard
  • Compressed solid composition for MRI
    Patent number: 10912847
    Abstract: The present invention relates to a compressed solid composition for MRI comprising a physiologically acceptable manganese (II) compound, its preparation and use for preparing an oral solution.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: February 9, 2021
    Assignee: Ascelia Pharma AB
    Inventors: Bent Højgaard, Magnus Olafsson Corfitzen, Dorthe Da Graca Couto Thrige
  • TESOFENSINE AND BETA BLOCKER COMBINATION FORMULATIONS
    Publication number: 20210023050
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically accetpable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Application
    Filed: October 9, 2020
    Publication date: January 28, 2021
    Inventors: Peter G. NIELSEN, Mikael S. THOMSEN, Bent HØJGAARD
  • COMPRESSED SOLID COMPOSITION FOR MRI
    Publication number: 20200384129
    Abstract: The present invention relates to a compressed solid composition for MRI comprising a physiologically acceptable manganese (II) compound, its preparation and use for preparing an oral solution.
    Type: Application
    Filed: June 8, 2020
    Publication date: December 10, 2020
    Inventors: Bent Højgaard, Magnus Olafsson Corfitzen, Dorthe Da Graca Couto Thrige
  • Tesofensine and beta blocker combination formulations
    Patent number: 10828278
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: November 10, 2020
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • COMPOSITION COMPRISING SUPLATAST TOSILATE
    Publication number: 20200230083
    Abstract: Provided is a pharmaceutical composition comprising suplatast tosilate or pharmaceutically acceptable derivatives thereof that provides for a constant exposure of the compound.
    Type: Application
    Filed: August 28, 2018
    Publication date: July 23, 2020
    Inventors: John Bondo Hansen, Mikael Søndergård Thomsen, Bent Højgaard
  • TESOFENSINE AND BETA BLOCKER COMBINATION FORMULATIONS
    Publication number: 20200129478
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Application
    Filed: December 6, 2019
    Publication date: April 30, 2020
    Inventors: Peter G. NIELSEN, Mikael S. THOMSEN, Bent HØJGAARD
  • Tesofensine and beta blocker combination formulations
    Patent number: 10537551
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: January 21, 2020
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • Extended release nicotinamide formulation
    Patent number: 10456389
    Abstract: The invention provides various extended release granules of nicotinamide. Granule properties can be enhanced by the inclusion of a conductive filler.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: October 29, 2019
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Bent Højgaard, Jørgen Wittendorff
  • PULSATILE DRUG DELIVERY SYSTEM FOR TREATING MORNING AKINESIA
    Publication number: 20190290587
    Abstract: Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.
    Type: Application
    Filed: July 11, 2017
    Publication date: September 26, 2019
    Inventors: John Bondo Hansen, Mikael Søndergård Thomsen, Ann Vivian Fullerton, Bent Højgaard, Peter Gudmund Nielsen
  • Tesofensine, beta blocker combination formulation
    Patent number: 10231951
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: March 19, 2019
    Assignee: SANIONA A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • TESOFENSINE AND BETA BLOCKER COMBINATION FORMULATIONS
    Publication number: 20180360804
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Inventors: Peter G. NIELSEN, Mikael S. THOMSEN, Bent HØJGAARD